NCT05559645View on ClinicalTrials.gov

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

NARecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

DZD9008

Daily dosing of DZD9008 200mg

DRUG

DZD9008

Daily dosing of DZD9008 300mg

Trial Locations (1)

100730

RECRUITING

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER

NCT05559645 - Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) | Biotech Hunter | Biotech Hunter